A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.

Described herein are Siglec ligand-antibody conjugates and compositions thereof that are useful for suppressing unwanted immune responses such as allergies and anaphylaxis.

The present invention refers to a composition for use in the prevention and/or treatment of dysbiosis. It also refers to the use of said composition for preparing a medicament for the prevention and/or treatment of dysbiosis. Furthermore, it refers to a method of preventing and/or treating of dysbiosis in which said composition is administered to a subject in need thereof.

The present invention relates to compounds of formula (I), wherein R.sup.1 to R.sup.3, m and n are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

##STR00001##

Disclosed herein are compounds of Formula (I) which inhibit, regulate and/or modulate tyrosine kinase receptors, particularly Ax1 and Mer signal transduction pathways related to the changes in cellular activities, compositions containing the compounds, methods of using the compounds to treat kinase-dependent diseases and conditions, and methods for making the compounds.

##STR00001##

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows:

##STR00001##

wherein R.sup.1a, R.sup.1b, R.sup.2, and R.sup.3, are defined herein.

This document provides compounds that are inhibitors of NF-κB activity, as well as the methods of using such compounds for treating diseases and conditions such as cancer, inflammatory conditions, or autoimmune diseases.

Disclosed herein are compositions and methods for the treatment and/or detection of diseases such as, but not limited to Lyme disease, Lyme disease-related disorders including post-treatment Lyme disease syndrome (PTLDS), chronic Lyme disease (CLD) and/or inflammation.

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, where the substituents are as defined herein. Pharmaceutical compositions including the same and method of using the same are also described.

##STR00001##